Stable isotope-assisted metabolomics in cancer research

IUBMB Life

Volumn 60, Issue 2, 2008, Pages 124-129

  Lane, Andrew N ^a,b   Fan, Teresa W M ^a,b   Higashi, Richard M ^a,b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Isotopomer pathway analysis; Mass spectrometry; NMR; Stable Isotopes

Indexed keywords

CARBON 13; NITROGEN 15; STABLE ISOTOPE; CARBON; DIAGNOSTIC AGENT; HYDROGEN; NITROGEN;

CANCER CELL; CANCER RESEARCH; CELL METABOLISM; CELL PROLIFERATION; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; REVIEW; ANIMAL; CELL CULTURE; METABOLISM; NEOPLASM;

ANIMALS; CARBON ISOTOPES; HUMANS; HYDROGEN; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; NITROGEN ISOTOPES; TUMOR CELLS, CULTURED;

EID: 42149164983     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.17     Document Type: Review

References (40)

1. Griffin, J. L. (2006) Understanding mouse models of disease through metabolomics. Curr. Opin. Chem. Biol., 10, 309-315.
2. Weljie, A. M., Newton, J., Mercier, P., Carlson, E., and Slupsky, C. M. (2006) Targeted profiling: quantitative analysis of h-1 nmr metabolomics data. Anal. Chem. 78, 4430-4442.
3. Lindon, J. C., Holmes, E., and Nicholson, J. K. (2004) Metabonomics: systems biology in pharmaceutical research and development. Curr. Opin. Mol. Therap. 6, 265-272.
4. Lindon, J. C., Nicholson, J. K., and Everett, J. R. (1999). NMR spectroscopy of biofluids. In Annual Reports on NMR Spectroscopy, Vol. 38. pp 1-88, Academic Press Inc: San Diego.
5. Fan, T. W. M., Lane, A. N., and Higashi, R. M. (2004) The promise of metabolomics in cancer molecular therapeutics. Curr. Opin. Mol. Therap. 6, 584-592.
6. Griffin, J. L. and Kauppinen, R. A. (2007) Tumour metabolomics in animal models of human cancer. Journal of Proteome Res. 6, 498-505. (Pubitemid 46340153)
7. Ippolito, J. E., Xu, J., Jain, S. J., Moulder, K., Mennerick, S., Crowley, J. R., Townsend, R. R., and Gordon, J. I. (2005) An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc. Natl. Acad. Sci. USA 102, 9901-9906.
8. Zimmermann, D., Hartmann, M., Moyer, M. P., Nolte, J., and Baumbach, J. I. (2007) Determination of volatile products of human colon cell line metabolism by gc/ms analysis. Metabolomics 3, 13-17. (Pubitemid 46443553)
9. Kind, T., Tolstikov, V., Fiehn, O., and Weiss, R. H. (2007) A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal. Biochem. 363, 185-195.
10. Beger, R. D., Schnackenberg, L. K., Holland, R. D., Li, D. H., and Dragan, Y. (2006) Metabonomic models of human pancreatic cancer using 1d proton NMR spectra of lipids in plasma. Metabolomics 2, 125-134.
11. Mackinnon, W. B., Barry, P. A., Malycha, P. L., Gillett, D. J., Russell, P., Lean, C. L., Doran, S. T., Barraclough, B. H., Bilous, M., and Mountford, C. E. (1997) Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 204, 661-666. (Pubitemid 27369023)
12. Glunde, K., Jie, C., and Bhujwalla, Z. M. (2004) Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 64, 4270-4276. (Pubitemid 38802433)
13. Eliyahu, G., Kreizman, T., and Degani, H. (2007) Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer 120, 1721-1730. (Pubitemid 46402874)
14. Katz-Brull, R., Seger, D., Rivenson-Segal, D., Rushkin, E., and Degani, H. (2002) Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 62, 1966-1970. (Pubitemid 34408439)
15. Glunde, K., and Serkova, N. J. (2006) Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7, 1109-1123. (Pubitemid 44644788)
16. Glunde, K., Raman, V., Mori, N., and Bhujwalla, Z. M. (2005) RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 65, 11034-11043. (Pubitemid 41713374)
17. De Molina, A. R., Gallego-Ortega, D., Sarmentero, J., Banez-Coronel, M., Martin-Cantalejo, Y., and Lacal, J. C. (2005) Choline kinase is a novel oncogene that potentiates rhoa-induced carcinogenesis. Cancer Res. 65, 5647-5653. (Pubitemid 40911165)
18. Lean, C. L., Bourne, R., Thompson, J. F., Scolyer, R. A., Stretch, J., Li, L. X. L., Russell, P., and Mountford, C. (2003) Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens. Melanoma Res. 13, 259-261. (Pubitemid 36683768)
19. Fan, T., Bandura, L., Higashi, R., and Lane, A. (2005) Metabolomics-edited transcriptomics analysis of SE anticancer action in human lung cancer cells. Metabolomics 1, 325-339. (Pubitemid 43949748)
20. Fan, T. W. M., Higashi, R. M., and Lane, A. N. (2006) Integrating metabolomics and transcriptomics for probing Se anticancer mechanisms. Drug Metab. Rev. 38, 707-732.
21. Lane, A. N., Fan, T. W., and Higashi, R. M. (2007). Isotopomer-based metabolomic analysis by NMR and mass spectrometry. In Biophysical Tools for Biologists (William Detrich, H. and Correia, J. J., eds.). p. 541-588, Chapter 18. Academic Press, San Diego, CA.
22. Brown, S. C., Kruppa, G., and Dasseux, J. L. (2005) Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrom. Rev. 24, 223-231.
23. Dhital, K., Saunders, C. A., Seed, P. T., O'doherty, M. J., and Dussek, J. (2000) (18)f]fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur. J. Cardiothorac. Surg. 18, 425-428.
24. Garber, K. (2004) Energy boost: the warburg effect returns in a new theory of cancer. J. Natl. Cancer Inst. 96, 1805-1806.
25. Warburg, O. (1956) On the origin of cancer cells. Science 123, 309-314.
26. Berggren, M. I., Husbeck, B., Samulitis, B., Baker, A. F., Gallegos, A., and Powis, G. (2001) Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch. Biochem. Biophys. 392, 103-109.
27. Boros, L. G. (2005) Metabolic targeted therapy of cancer: current tracer technologies and future drug design strategies in the old metabolic network. Metabolomics 1, 11-15.
28. Serkova, N. and Boros, L. G. (2005) Detection of resistance to imatinib by metabolic profiling - clinical and drug development implications. Am. J. Pharmacogenomics 5, 293-302. (Pubitemid 41425607)
29. Boren, J., Cascante, M., Marin, S., Comin- And uix, B., Centelles, J. J., Lim, S., Bassilian, S., Ahmed, S., Lee, W. N. P., and Boros, L. G. (2001) Gleevec (st1571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J. Biol. Chem. 276, 37747-37753.
30. Vizan, P., Boros, L. G., Figueras, A., Capella, G., Mangues, R., Bassilian, S., Lim, S., Lee, W.-N. P., and Cascante, M. (2005) K-ras codon-specific mutations produce distinctive metabolic phenotypes in human fibroblasts. Cancer Res. 65, 5512-5515. (Pubitemid 40911149)
31. Lane, A. N., and Fan, T. W. (2007) Quantification and identification of isotopomer distributions of metabolites in crude cell extracts using 1H tocsy. Metabolomics 3, 79-86.
32. Miccheli, A., Tomassini, A., Puccetti, C., Valerio, M., Peluso, G., Tuccillo, F., Calvani, M., Manetti, C., and Conti, F. (2006) Metabolic profiling by c-13-NMR spectroscopy: [1,2-c-13(2)] glucose reveals a heterogeneous metabolism in human leukemia t cells. Biochimie 88, 437-448.
33. Forbes, N. S., Meadows, A. L., Clark, D. S., and Blanch, H. W. (2006) Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab. Eng. 8, 639-652.
34. Medina, M. A. (2001) Glutamine and cancer. J Nutr. 131, 2539S-2542S.
35. Mazurek, S., and Eigenbrodt, E. (2003) The tumor metabolome. Anticancer Res. 23, 1149-1154.
36. Portais, J. C., Voisin, P., Merle, M., and Canioni, P. (1996) Glucose and glutamine metabolism in c6 glioma cells studied by carbon 13 NMR. Biochimie 78, 155-164. (Pubitemid 26234302)
37. Al-Saffar, N. M. S., Troy, H., De Molina, A. R., Jackson, L. E., Madhu, B., Griffiths, J. R., Leach, M. O., Workman, P., Lacal, J. C., Judson, I. R., and Chung, Y. L. (2006) Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor mn58b in human carcinoma models. Cancer Res. 66, 427-434. (Pubitemid 43166051)
38. Mcculloch, M., Jezierski, T., Broffman, M., Hubbard, A., Turner, K., and Janecki, T. (2006) Diagnostic accuracy of canine scent detection in early-and late-stage lung and breast cancers. Integr Cancer Ther 5, 30-39. (Pubitemid 43260792)
39. Phillips, M., Gleeson, K., Hughes, J. M. B., Greenberg, J., Cataneo, R. N., Baker, L., and Mcvay, W. P. (1999) Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 353, 1930-1933. (Pubitemid 29255706)
40. Phillips, M., Herrera, J., Krishnan, S., Zain, M., Greenberg, J., and Cataneo, R. N. (1999) Variation in volatile organic compounds in the breath of normal humans. J. Chromatogr. B 729, 75-88. (Pubitemid 29264111)